MustGrow Biologics Isolates Third Molecule From Mustard Plant
MustGrow Biologics (CSE: MGRO) continues to conduct research on the mustard plant and extract different molecules. The firm this morning
Read moreMustGrow Biologics (CSE: MGRO) continues to conduct research on the mustard plant and extract different molecules. The firm this morning
Read moreWednesday, Antibe Therapeutics (TSX: ATE) announced that they closed their bought deal financing. The bought deal was for 6.7 million
Read moreRelay Medical (CSE: RELA) this afternoon announced that it has seen its joint venture, Fionet Rapid Response Group, engaged by
Read moreMoney continues to be raised at a feverish pace in the capital markets, with Antibe Therapeutics (TSX: ATE) the latest
Read moreLast week’s announcement that Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has agreed to buy GW Pharmaceuticals (NASDAQ: GWPH) for US$7.2 billion
Read moreEarlier this week, Antibe Therapeutics (TSXV: ATE) announced a strategic licensing deal with Nuance Pharm in China. The deal includes
Read moreRevive Therapeutics (CSE: RVV) this morning provided an update in connection with its ongoing cannabinoid pharmaceuticals program. More specifically, the
Read moreMustGrow Biologics (CSE: MGRO) has seen further validation of its proprietary mustard derived biopesticide following further laboratory results. The latest
Read moreMustGrow Biologics (CSE: MGRO) has seen further success with its mustard-derived biopesticide, this morning announcing that third party independent testing
Read moreWillow Biosciences (TSX: WLLW) this morning had a major announcement, with the company announcing that it has advanced its work
Read more